PL3076985T3 - Kompozycja zawierająca probiotyki z nadekspresją białka clpb do zastosowania w leczeniu otyłości - Google Patents
Kompozycja zawierająca probiotyki z nadekspresją białka clpb do zastosowania w leczeniu otyłościInfo
- Publication number
- PL3076985T3 PL3076985T3 PL14806649.1T PL14806649T PL3076985T3 PL 3076985 T3 PL3076985 T3 PL 3076985T3 PL 14806649 T PL14806649 T PL 14806649T PL 3076985 T3 PL3076985 T3 PL 3076985T3
- Authority
- PL
- Poland
- Prior art keywords
- overexpression
- obesity
- treatment
- composition containing
- containing probiotics
- Prior art date
Links
- 102100034663 Caseinolytic peptidase B protein homolog Human genes 0.000 title 1
- 101000946436 Homo sapiens Caseinolytic peptidase B protein homolog Proteins 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 230000002018 overexpression Effects 0.000 title 1
- 239000006041 probiotic Substances 0.000 title 1
- 235000018291 probiotics Nutrition 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/02—Nutritional disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306673 | 2013-12-05 | ||
| EP14306552 | 2014-10-02 | ||
| PCT/EP2014/076611 WO2015082633A1 (en) | 2013-12-05 | 2014-12-04 | Bacterial influence on regulation of appetite via clpb protein mimicry of alpha-msh |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3076985T3 true PL3076985T3 (pl) | 2024-12-16 |
Family
ID=52007031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14806649.1T PL3076985T3 (pl) | 2013-12-05 | 2014-12-04 | Kompozycja zawierająca probiotyki z nadekspresją białka clpb do zastosowania w leczeniu otyłości |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20160313348A1 (pl) |
| EP (1) | EP3076985B1 (pl) |
| JP (2) | JP2017503768A (pl) |
| KR (1) | KR102332078B1 (pl) |
| CN (1) | CN106061491B (pl) |
| CA (1) | CA2932488A1 (pl) |
| ES (1) | ES2994101T3 (pl) |
| HR (1) | HRP20241279T1 (pl) |
| PL (1) | PL3076985T3 (pl) |
| WO (1) | WO2015082633A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3769777B9 (en) * | 2014-10-02 | 2022-10-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof |
| US10682389B2 (en) | 2015-06-05 | 2020-06-16 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof |
| AU2017247612B2 (en) * | 2016-04-05 | 2023-12-07 | Centre Hospitalier Universitaire De Rouen | Hafnia alvei based pharmaceutical and food compositions for inducing satiation and prolonging satiety |
| EP3385276A1 (en) * | 2017-04-03 | 2018-10-10 | Targedys | Proteins derived from clpb and uses thereof |
| EP3384922A1 (en) * | 2017-04-03 | 2018-10-10 | Targedys | Brassicaceae protein extract and uses thereof |
| US20220323376A1 (en) * | 2019-05-01 | 2022-10-13 | New York University | Methods and compositions for sensitizing cancer cells to drug-induced apoptosis |
| EP4426325A1 (en) | 2021-11-03 | 2024-09-11 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Oxytocin-mimetic compositions and uses thereof |
| EP4176890A1 (en) | 2021-11-03 | 2023-05-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Oxytocin-mimetic compositions and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6343696A (en) | 1995-07-07 | 1997-02-10 | Oravax, Inc | Helicobacter clpb |
| JP2009524640A (ja) | 2006-01-27 | 2009-07-02 | ダニスコ エー/エス | 肥満及びそれに関連する疾患の治療及び予防のためのプロバイオティック微生物の使用 |
| EP2053122A1 (en) * | 2007-10-23 | 2009-04-29 | Nestec S.A. | Stress tolerant bifidobacteria |
| WO2012011174A1 (ja) * | 2010-07-22 | 2012-01-26 | ビオフェルミン製薬株式会社 | 脂質代謝改善剤、脂質代謝改善作用増強剤、抗肥満剤及び抗肥満作用増強剤 |
| KR20160101945A (ko) * | 2013-12-05 | 2016-08-26 | 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) | a-MSH의 ClpB 단백질 모방을 통한 숙주 급식 및 감정의 세균 영향 |
-
2014
- 2014-12-04 CN CN201480066463.6A patent/CN106061491B/zh active Active
- 2014-12-04 CA CA2932488A patent/CA2932488A1/en not_active Abandoned
- 2014-12-04 KR KR1020167017273A patent/KR102332078B1/ko active Active
- 2014-12-04 US US15/101,452 patent/US20160313348A1/en not_active Abandoned
- 2014-12-04 EP EP14806649.1A patent/EP3076985B1/en active Active
- 2014-12-04 ES ES14806649T patent/ES2994101T3/es active Active
- 2014-12-04 HR HRP20241279TT patent/HRP20241279T1/hr unknown
- 2014-12-04 WO PCT/EP2014/076611 patent/WO2015082633A1/en not_active Ceased
- 2014-12-04 PL PL14806649.1T patent/PL3076985T3/pl unknown
- 2014-12-04 JP JP2016536831A patent/JP2017503768A/ja active Pending
-
2019
- 2019-02-06 JP JP2019019913A patent/JP6876732B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160101944A (ko) | 2016-08-26 |
| JP2017503768A (ja) | 2017-02-02 |
| EP3076985C0 (en) | 2024-07-24 |
| ES2994101T3 (en) | 2025-01-17 |
| CN106061491A (zh) | 2016-10-26 |
| HRP20241279T1 (hr) | 2024-12-06 |
| WO2015082633A1 (en) | 2015-06-11 |
| EP3076985A1 (en) | 2016-10-12 |
| EP3076985B1 (en) | 2024-07-24 |
| JP2019089815A (ja) | 2019-06-13 |
| JP6876732B2 (ja) | 2021-05-26 |
| CA2932488A1 (en) | 2015-06-11 |
| KR102332078B1 (ko) | 2021-11-26 |
| CN106061491B (zh) | 2021-01-08 |
| US20160313348A1 (en) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276106A (en) | Garp-binding proteins and their uses | |
| GB2516335B (en) | The use of phytocannabinoids in the treatment of ovarian carcinoma | |
| SI3329909T1 (sl) | Fenfluramin za uporabo pri zdravljenju Dravetovega sindroma | |
| PL3542798T3 (pl) | Aceklidyna do zastosowania w leczeniu starczowzroczności | |
| IL244111A0 (en) | The survival benefit of patients with resistant tumors with high levels of c-creative protein | |
| PL3489261T3 (pl) | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu | |
| PL3076985T3 (pl) | Kompozycja zawierająca probiotyki z nadekspresją białka clpb do zastosowania w leczeniu otyłości | |
| IL242483B (en) | Preparations containing omomyc and their use for cancer treatment | |
| SG11201509782TA (en) | Compositions and methods for the treatment of diabetes and pre-diabetes | |
| PL3044229T3 (pl) | Peptydy do zastosowania w leczeniu zapalenia błony śluzowej jamy ustnej | |
| SG11201510150VA (en) | Immunotherapy composition and use thereof | |
| PL2910131T3 (pl) | Kompozycja przeciwdziałająca zmęczeniu i jej zastosowanie | |
| ZA201508050B (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| PT3074033T (pt) | Compostos para o tratamento de obesidade e métodos de utilização dos mesmos | |
| PL2943215T3 (pl) | Peptydy pochodzące z laktoferycyny do zastosowania w leczeniu nowotworu | |
| SG11201601263WA (en) | Recombinant microorganisms and methods of use thereof | |
| GB201314623D0 (en) | Novel mucinase for use in therapy or prophylaxis |